{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:20Z","timestamp":1793915300890,"version":"4.8.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      To evaluate and compare the therapeutic response, progression-free survival (PFS), overall survival (OS), and clinical toxicity of targeted alpha therapy (TAT) [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and salvage [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumor (NET) patients who showed an objective response or disease stabilization following an initial course of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE PRRT and eventually developed progressive disease after a time interval of more than 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      This was a single-institution, retrospective observational analysis conducted at a tertiary care institute. The medical records of metastatic NET patients who had been previously treated with an initial course of PRRT (I-PRRT) with 4\u20136 cycles of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE and showed an objective response or stable disease (SD) on the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria after I-PRRT, but eventually developed progressive disease (PD) after a time gap of more than 6 months, and subsequently received [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE or salvage [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE were analyzed. These patients with matched baseline characteristics (site of primary disease, WHO grading of tumors, Ki-67 index, disease burden, [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-FDG avidity, and previously treatments) were divided into the 2 treatment arms based on the treatment received by them, which in turn depended upon availability of therapeutic radionuclide, patient choice, and financial constraints as follows: Arm A: [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and Arm B: salvage [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE. The treatment response was evaluated under 3 categories for all patients: (a) symptomatic, (b) biochemical, and (c) functional and anatomic imaging response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 40 patients with metastatic NET (20 in each arm) were included and analyzed in the study. On the symptomatic response, 3 (15%) patients demonstrated a complete response (CR), and 7 (35%) patients demonstrated partial response (PR) in arm A, compared with no CR and PR of 4 (20%) patients in arm B. Biochemical response assessed by using serum CgA showed partial improvement in 10 (50%) patients in arm A versus 5 (25%) patients in arm B. On anatomic imaging, the disease control rate (DCR) was found to be 80% in arm A and 60% in arm B. The objective response rate (ORR) calculated based upon RECIST 1.1 criteria was 35% in arm A and 10% in arm B. The median progression-free survival was 10 months (95% CI, 6.0\u201324.0) in arm A and 12 months (95% CI, 4.0\u201333.0) in arm B, while the median overall survival was 16 months (95% CI, 10\u201316) in arm A and was not reached in arm B; neither difference reached statistical significance. Toxicities in both arms were predominantly mild and manageable, with no grade 3 or higher adverse events in either arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      This observational study shows that [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-DOTATATE and salvage PRRT with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE are both efficacious and well-tolerated treatments for progressive metastatic NETs without high-grade toxicity. The numerically superior clinical, biochemical, and imaging response rates observed with TAT indicate that alpha-emitting radionuclides may partly overcome resistance to prior beta-emitter therapy. Prospective, larger multicenter randomized trials are needed to validate these findings, refine patient selection, and determine the appropriate treatment of alpha- or salvage beta-emitting radionuclide therapies in progressive NETs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006578","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:53Z","timestamp":1781647313000},"page":"e877-e885","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Targeted Alpha Therapy With [225Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT With [177Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [177Lu]Lu-DOTATATE Treatment"],"prefix":"10.1097","volume":"51","author":[{"given":"Roopal","family":"Agrawal","sequence":"first","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Parel"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul V.","family":"Parghane","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Parel"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Basu","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Parel"},{"name":"Homi Bhabha National Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.3390\/jcm12155138","article-title":"A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management","volume":"12","author":"Sultana","year":"2023","journal-title":"J Clin Med"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000473892","article-title":"ENETS Consensus Guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy","volume":"105","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","article-title":"Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival","volume":"19","author":"Rudisile","year":"2019","journal-title":"BMC Cancer"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4274\/mirt.galenos.2023.38258","article-title":"Initial findings on the use of [225Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors","volume":"32","author":"Demirci","year":"2023","journal-title":"Mol Imaging Radionucl Ther"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2967\/jnumed.122.264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study","volume":"64","author":"Ballal","year":"2023","journal-title":"J Nucl Med"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"1696063","DOI":"10.3389\/fonc.2025.1696063","article-title":"The therapeutic efficacy of 225Ac-DOTATATE in neuroendocrine tumors: a preliminary meta-analysis","volume":"15","author":"Ma","year":"2025","journal-title":"Front Oncol"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"JH","year":"2016","journal-title":"Radiology"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"e389278","DOI":"10.1200\/EDBK_389278","article-title":"Therapy sequencing in patients with advanced neuroendocrine neoplasms","volume":"43","author":"Riechelmann","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R15-20260908","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"key":"R16-20260908","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.2147\/CMAR.S372776","article-title":"Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis","volume":"14","author":"Arrivi","year":"2022","journal-title":"Cancer Manag Res"},{"key":"R17-20260908","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","article-title":"Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors","volume":"27","author":"McCollum","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"R18-20260908","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R19-20260908","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"R20-20260908","doi-asserted-by":"crossref","first-page":"17588359241286751","DOI":"10.1177\/17588359241286751","article-title":"Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review","volume":"16","author":"Taboada","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"R21-20260908","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-20260908","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"key":"R23-20260908","doi-asserted-by":"crossref","first-page":"20210896","DOI":"10.1259\/bjr.20210896","article-title":"The efficacy, toxicity and survival of salvage retreatment PRRT with 177Lu-DOTATATE in patients with progressive NET following initial course of PRRT","volume":"95","author":"Sitani","year":"2022","journal-title":"Br J Radiol"},{"key":"R24-20260908","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNM.0000000000001350","article-title":"Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"42","author":"Kim","year":"2021","journal-title":"Nucl Med Commun"},{"key":"R25-20260908","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20260908","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:34Z","timestamp":1788901234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006578"}},"subtitle":["An Observational Study Comparing the Therapeutic Response, Survival, and Clinical Toxicity"],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006578","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}